Erika Hamilton, MD, director of Breast Cancer Research at the Sarah Cannon Research Institute, discusses some of the emerging ...

BC, and Sandra Sepulveda, AGPNP-BC, MSN, BMTCN, discussed what went into developing this Malignant Hematology and Bone Marrow ...

Aumolertinib improved progression-free survival vs placebo in patients with unresectable stage III non–small cell lung cancer ...

During a Case-Based Roundtable® event, Saad Z. Usmani, MD, FACP, MBA, discussed CAR T-cell therapy as third-line therapy for ...

Noah S. Kalman, MD, MBA, discusses the most common types of thyroid cancer and their respective prognosis.

Jacob Stein, MD, MPH, discusses how nab-sirolimus improves outcomes for patients with advanced perivascular epithelioid cell tumors compared with other treatments or no treatment options.

Panelist discusses how agents such as osimertinib, initially developed to target resistance mechanisms in refractory disease, ...

John Seymour, MD, discusses the development and clinical application of BCL-2 inhibitors for the treatment of CLL.

In an interview with Targeted Oncology, Erika Hamilton, MD, discussed emerging endocrine therapies that are advancing breast ...

The FDA accepted the new drug application for TLX101-CDx and granted priority review to the agent in glioma. The FDA has ...

Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of ...

Recent advancements in protein engineering, especially antibody-drug conjugates, show promise in lung cancer treatment, with ...